Das 10. Immuno-Onkologie-Symposium wird Forscher und Kliniker zusammenbringen, um Innovationen zu diskutieren, die die Zukunft der Immuno-Onkologie bestimmen. Zu den Themen gehören Behandlungskonzepte wie Immune Engagers, zelluläre Therapien, Immun-Checkpoint-Inhibition und modernste grundlagenwissenschaftliche Ansätze zum Verständnis von Wirkmechanismen, Resistenzen und Nebenwirkungen von Krebsimmuntherapien.
Universitätsspital Zürich
Rämistrasse 100
8091 Zürich
oder ONLINE
Grosser Hörsaal NORD
06.03.2026
08:30 - 16:50
SGMO 7
kostenlos
| 8.30 a.m. | Welcome Markus G. Manz, University Hospital ZurichTobias Weiss, University Hospital Zurich |
| Immune Checkpoint Inhibition Andreas Wicki / Anne Müller |
|
| 8.35 a.m. | Identification of a novel checkpoint for tumour immunogenicity Sergio Quezada, University College London Cancer Institute, United Kingdom |
| 9.00 a.m. | When self-reactivity becomes protective: autoimmunity and tumor control under checkpoint inhibitiors Lukas Flatz, Prof. Dr. med., University Hospital Tübingen, Germany |
| 9.25 a.m. | Current and future immune checkpoint inhibitor strategies: Combinations and novel targets Caroline Robert, MD, PhD, Gustave Roussy and Paris Saclay University, France |
| 9.50 a.m. | Flash Talk Immune Checkpoint Inhibition
Immune Microenvironment Modulation in Experimental Glioma by Combining CDK4/6 Inhibition with PD-1 Blockade Immunocompetent Cancer-on-Chip Models to Assess Safety and Efficacy of New Drug Modalities |
| 9.55 a.m. | Coffee Break |
| Immune Engagers Markus G. Manz / Melanie Greter |
|
| 10.15 a.m. | State of the art of T cell engagers and emerging next-generation cell therapies Dario Vernetz, Principal Scientist at Roche |
| 10.40 a.m. | Next-Generation enineering of T cell immunity Mirco Julian Friedrich, Dr. , German Cancer Research Center (DKFZ), Heidelberg, Germany |
| 11.05 a.m. | Reprogramming tumor-associated macrophages Peter Ellmark, Professor at Lund University, CSO at Alligator Bioscience, Sweden |
| 11.30 a.m. | Bifunctional Paghocytic Synapse Enhancers for Cancer Immunotherapy Valerio Sabatino, University of Basel, Switzerland |
| 11.55 a.m. | Flash Talk Immune Engagers
Combinatorial treatment with small molecule inhibitors abrogates systemic toxicity of tumor-targeted cytokine fusion protein PRO-XTEN masked T cell engagers, enabling protease-specific activation only in the tumor microenvironment to mitigate damage to healthy tissues and reduce toxicity |
| 12.00 p.m. | Lunch Break |
| Cellular Therapies Tobias Weiss / Chiara Magnani |
|
| 12.50 p.m. | iPSC-CAR immune cells as a novel concept for cell therapy Maria Themeli, Amsterdam (TiPSC), The Netherlands |
| 1.15 p.m. | Optimising CAR-T cells for improved efficacy and reduced toxicity Prof. Magnus Essand, PhD, Uppsala University, Dept. Immunology, Genetics, Pathology, Uppsala Sweden |
| 1.40 p.m. | Immunotherapy for brain tumors – from vaccines to TCR T cell therapy Michael Platten, MD CCU Neuroimmunology and Brain Tumor Immunology, DKFZ Heidelberg, Germany |
| 2.05 p.m. | Current and future concepts of in vivo engineered CAR immune cells Christian Buchholz, Prof. Dr., Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut Langen, Germany |
| 2.30 p.m. | Flash Talk Cellular Therapies
Tumor-restricted IL-12 secreting VEGFR2-SynNotch-CAR-T cells overcome antigen escape in murine glioma Combining CAR T Cell Therapy and Inhibitory Receptor Targeting for the Treatment of AML |
| 2.35 p.m. | Coffee Break |
| Mechanisms, Profiling and Basic Science Aspects of Cancer Immunotherapies Burkhard Becher / Stefanie Kreutmair |
|
| 2.55 p.m. | The Double-Edged Sword of Cancer Immunity: Escape Mechanisms and Therapy-Induced Side Effects Robert Zeiser, Uniklinik Freiburg, Germany |
| 3.20 p.m. | Lymphocyte Networks Orchestrating Colorectal Cancer Liver Metastases Sonia Tugues, PhD, Prof., Mannheim Institute for Innate Immunoscience (MI3), University of Heidelberg, Germany; Institute of Experimental Immunology, University of Zurich |
| 3.45 p.m. | Modeling and modulating antitumor immunity in human cancer tissues Dr. Daniela Thommen, Netherlands Cancer Institute, Amsterdam, Netherlands |
| 4.10 p.m. | The tumor microenvironment from a T-cell-centered view Enrico Lugli, PhD, Humanitas Research Hospital Pieve Emanuele, Italy |
| 4.35 p.m. | Flash Talk Mechanisms, Profiling and Basic Science Aspects
Penk-expressing Tregs drive proinflammatory DCs and enhance tumour control Ms4a7+ Monocyte-Derived Macrophages in Tumor Immunity |
| 4.40 p.m. | Wrap-Up Markus G. Manz, University Hospital ZurichTobias Weiss, University Hospital Zurich |
Bitte melden Sie sich bis zum 05.03.2026 an.